Regeneron (REGN) Files Mixed Shelf Registration Statement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron Pharma (REGN) PT Lowered to $680 at Evercore ISI
November 4, 2021 4:11 PM EDTEvercore ISI analyst Dr. Josh Schimmer lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $680.00 (from $690.00) while maintaining a Outperform rating.... More
Regeneron beats quarterly sales on COVID-19 drug demand
November 4, 2021 6:42 AM EDT(Reuters) -Regeneron Pharmaceuticals Inc on Thursday reported higher-than-expected quarterly revenue on strong demand for its COVID-19 antibody cocktail during the Delta variant-led surge in infections in the United States.
U.S. sales of the cocktail, REGEN-COV, approved for emergency use in non-hospitalized COVID-19 patients, were $676.7 million in the third quarter, compared with analysts' estimates of $320.5... More
Regeneron (REGN) Tops Q3 EPS by $6.15
November 4, 2021 6:37 AM EDTRegeneron (NASDAQ: REGN) reported Q3 EPS of $15.37, $6.15 better than the analyst estimate of $9.22. Revenue for the quarter came in at $3.45 billion versus the consensus estimate of $2.76 billion.
For earnings history and earnings-related data on Regeneron (REGN) click here.
... More